- Home
- AQB vs XRTX Comparison
AQB vs XRTX Comparison
Compare AQB & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | XRTX |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.3M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AQB | XRTX |
|---|---|---|
| Price | $0.92 | $2.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.2K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,472,659.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $0.35 |
| 52 Week High | $2.95 | $3.60 |
Technical Indicators
Market Signals| Indicator | AQB | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 56.92 |
| Support Level | $0.86 | $0.41 |
| Resistance Level | $1.08 | $3.00 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 16.57 | 14.08 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.